Researchers from Guangzhou Institutes of Biomedicine and Health and CSIRO presented the discovery and preclinical characterization of novel compounds with high activity against androgen receptor (AR)-dependent prostate cancer cells.
Medshine Discovery Inc. has identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to an androgen receptor targeting moiety via a linker acting as androgen receptor degradation inducers reported to be useful for the treatment of cancer.
Asieris Pharmaceuticals Co. Ltd. has divulged 7-nitro-8-hydroxyquinoline derivatives reported to be useful for the treatment of urinary tract infections, and bladder and prostate cancer.
A new acute coronary syndrome detection system developed by Neuome Peptides Pte. Ltd.’s aims to make tests for the frequently lethal condition faster, more precise and less invasive. Neuome’s Truheart is a point-of-care assay for cardiovascular disease that is used in the company’s established Instadetect assay development platform. The assay measures the biomarkers troponins I and T and myoglobin.
Avenda Health Inc. secured FDA 510(k) clearance for its Iquest platform, which uses artificial intelligence to map the location of a tumor within the prostate. The visualization created provides better assessment of the extent of the malignancy and improves selection of treatments. Avenda raised $10 million in August to support development of Iquest, which guides the company’s Focalpoint laser ablation system.
Global interest in radiopharmaceuticals is growing, and some big deals in the space have sparked interest in the last few years. Novartis AG has spent about $6 billion in acquisitions and is seen as the global leader.
Global interest in radiopharmaceuticals is growing, and some big deals in the space have sparked interest in the last few years. Novartis AG has spent about $6 billion in acquisitions and is seen as the global leader.
The Cleveland Clinic Foundation has disclosed citron rho-interacting kinase (CRIK; CIT) inhibitors reported to be useful for the treatment of medulloblastoma and prostate cancer.
Researchers from the University of Zaragoza and Promontory Therapeutics Inc. have discovered that PT-112, which has a multimodal mechanism of action, could have different clinical applications in cancer treatment due to its effects on mitochondria in castration-resistant prostate cancer (CRPC). PT-112 is an immunogenic small molecule currently in phase II development in metastatic castration-resistant prostate cancer (mCRPC). The researchers designed PT-112 to target advanced solid tumors, such as thymus, small-cell, non-small-cell lung or CRPC.
